Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Authors

Kannan Sridharan, Ondrej Fiala, Gowri Sivaramakrishnan, Marc R Matrana, Thomas Büttner, Jakub Kucharz, Javier Molina Cerrillo, Patrizia Giannatempo, Zin W Myint, Alfonso Gómez de Liaño, Alina Pirshtuk, Augusto Mota, Ravindran Kanesvaran, Yüksel Ürün, Martin Angel, Tomas Soule, Francesco Massari, Joaquim Bellmunt, Shilpa Gupta, Matteo Santoni

Published in

Expert opinion on biological therapy. Aug 29, 2026. Epub Aug 29, 2026.

Abstract

Enfortumab vedotin (EV) has transformed treatment for advanced urothelial carcinoma (aUC), but outcomes vary. Machine learning (ML) with explainable artificial intelligence (XAI) may improve survival prediction.
Data from 544 aUC patients receiving EV after platinum chemotherapy and immunotherapy (51 centers, 24 countries) were analyzed. Four ML algorithms (Random Survival Forest, XGBoost, Elastic Net-regularized Cox, Support Vector Machine) were trained (80%) and tested (20%) to predict overall survival (OS). SHAP analysis (on best performing ML model) provided interpretability. Performance was assessed by C-index and time-dependent AUC.
XGBoost (C-index 0.59) and Elastic Net (C-index 0.60) showed best discrimination. XGBoost achieved highest time-dependent AUCs (0.77, 0.87, 0.93 at 1, 2, 3 years). SHAP identified prior immunotherapy (pembrolizumab, atezolizumab/nivolumab), radiotherapy, and upper tract tumors with lower mortality risk; lung, liver, bone, soft tissue metastases increased risk. ECOG performance status and metastatic distribution were key predictors.
ML with XAI identifies clinically plausible survival predictors in EV-treated aUC. XGBoost and Elastic Net offer modest risk stratification, that are hypothesis generating but does not support routine clinical use. Functional status, metastatic pattern, and treatment context are key drivers, providing a foundation for externally validated prognostic tools.

PMID:
42667292
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.